K2 Principal Fund, L.P. Gemini Therapeutics, Inc. Transaction History

K2 Principal Fund, L.P.

  • $210 Million
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022
SELL
$1.31 - $2.01 $130,503 - $200,238
-99,621 Reduced 34.03%
193,124 $317,000
Q2 2022

Aug 12, 2022
BUY
$1.22 - $1.73 $357,148 - $506,448
292,745 New
292,745 $495,000

Others Institutions Holding GMTX

# of Institutions
1
Shares Held
2.44M
Call Options Held
0
Put Options Held
0
View Full List

About Gemini Therapeutics, Inc.

GMTX Quotes by TradingView
  • Ticker GMTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,244,500
  • Market Cap $1.05B
  • Description
  • Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 ...
More about GMTX
Track This Portfolio

Track K2 Principal Fund, L.P. Portfolio

Follow K2 Principal Fund, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of K2 Principal Fund, L.P., based on Form 13F filings with the SEC.

News

Stay updated on K2 Principal Fund, L.P. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email